Abstract
Exercise therapy, especially when supervised on-site in a clinical facility or directed off-site for a home-based program, is an essential component of the management of coronary artery disease (CAD) and peripheral arterial disease (PAD). In the case of both atherosclerotic diseases, it can decrease adverse cardiovascular (CV) events. There has been a recent push toward invasive management of both CAD and PAD but accumulating clinical experience has shown the limitation of invasive management and emphasized the importance of medications, CV risk reduction, conditioning, and exercise, especially when supervised. Exercise results in increased peak oxygen consumption (V02), improvement of wellestablished CV risk factors such as plasma lipids, and an improvement in indicators of inflammation and of various metabolic factors. Fortunately, there is generally good third-party coverage of medications and vascular interventions but unfortunately, poor insurance coverage for supervised or directed exercise programs for which significant patient benefit has been established.
Keywords: Cardiovascular risk reduction, claudication, coronary artery disease, exercise training, low-density lipoprotein cholesterol, major adverse cardiac event, peripheral arterial disease, secondary prevention.
Current Vascular Pharmacology
Title:Increased Exercise Favorably Modifies Coronary Artery Disease and Peripheral Arterial Disease Outcomes
Volume: 14 Issue: 5
Author(s): Thomas F. Whayne and Debabrata Mukherjee
Affiliation:
Keywords: Cardiovascular risk reduction, claudication, coronary artery disease, exercise training, low-density lipoprotein cholesterol, major adverse cardiac event, peripheral arterial disease, secondary prevention.
Abstract: Exercise therapy, especially when supervised on-site in a clinical facility or directed off-site for a home-based program, is an essential component of the management of coronary artery disease (CAD) and peripheral arterial disease (PAD). In the case of both atherosclerotic diseases, it can decrease adverse cardiovascular (CV) events. There has been a recent push toward invasive management of both CAD and PAD but accumulating clinical experience has shown the limitation of invasive management and emphasized the importance of medications, CV risk reduction, conditioning, and exercise, especially when supervised. Exercise results in increased peak oxygen consumption (V02), improvement of wellestablished CV risk factors such as plasma lipids, and an improvement in indicators of inflammation and of various metabolic factors. Fortunately, there is generally good third-party coverage of medications and vascular interventions but unfortunately, poor insurance coverage for supervised or directed exercise programs for which significant patient benefit has been established.
Export Options
About this article
Cite this article as:
Whayne F. Thomas and Mukherjee Debabrata, Increased Exercise Favorably Modifies Coronary Artery Disease and Peripheral Arterial Disease Outcomes, Current Vascular Pharmacology 2016; 14 (5) . https://dx.doi.org/10.2174/1570161114999160719104936
DOI https://dx.doi.org/10.2174/1570161114999160719104936 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PGD and Prenatal Diagnosis: Comparison and Review in Different Genetic Disorders
Current Women`s Health Reviews Testosterone, Estradiol, and Sex Hormone-Binding Globulin in Alzheimer’s Disease: A Meta-Analysis
Current Alzheimer Research New Approaches to Atherosclerotic Cardiovascular Disease. The Potentialities of Torcetrapib
Recent Patents on Cardiovascular Drug Discovery Nanotechnology and Antioxidant Therapy: An Emerging Approach for Neurodegenerative Diseases
Current Medicinal Chemistry Molecules from Nature: Modulating the Expression of Estrogen Receptor Genes in Breast Cancer Cells
Current Bioactive Compounds Therapeutic Targeting of P-Selectin in Atherosclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Cytotoxic and Apoptotic Effect of <i>Iris taochia</i> Plant Extracts on Human Breast Cancer (MCF-7) Cells
Current Proteomics Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide
Current Drug Metabolism Parvalbumin as a Pleomorphic Protein
Current Protein & Peptide Science Editorial [Hot Topic: Modifying Cardiovascular Risk Factors: Epidemiology and Characteristics of Hypertension-Related Disorders (Executive Guest Editor: Aurelio Leone)]
Current Pharmaceutical Design CYP Epoxygenase Derived EETs: From Cardiovascular Protection to Human Cancer Therapy
Current Topics in Medicinal Chemistry Polyphenols: A Nutraceutical Approach Against Diseases
Recent Patents on Food, Nutrition & Agriculture Familial Combined Hyperlipidaemia: Under - Defined and Under - Diagnosed?
Current Vascular Pharmacology Pulmonary Vascular Function in Insulin Resistance and Diabetes
Current Vascular Pharmacology Cardiac Workup of Ischemic Stroke
Current Cardiology Reviews A Review on Noscapine, and its Impact on Heme Metabolism
Current Drug Metabolism Electroforming: from Rocket Engines to Nanotweezers
Micro and Nanosystems Prostaglandin EP Receptor Subtypes Involved in Regulating HCO3- Secretion from Gastroduodenal Mucosa
Current Pharmaceutical Design Nitric Oxide as a Marker for Levo-Thyroxine Therapy in Subclinical Hypothyroid Patients
Current Vascular Pharmacology Drugs Targeting Parasite Lysosomes
Current Pharmaceutical Design